A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients
Abstract Background Anthracycline usage has been linked to cardiovascular adverse events (CAEs), which is unpredictable. It is critical to identify the characteristics of vulnerable populations and risk factors in order to reduce the occurrence of CAEs. Objectives This meta-analysis aimed to assess...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13305-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571594044604416 |
|---|---|
| author | Bo Dai Jingjing Xu Baiyan Wang |
| author_facet | Bo Dai Jingjing Xu Baiyan Wang |
| author_sort | Bo Dai |
| collection | DOAJ |
| description | Abstract Background Anthracycline usage has been linked to cardiovascular adverse events (CAEs), which is unpredictable. It is critical to identify the characteristics of vulnerable populations and risk factors in order to reduce the occurrence of CAEs. Objectives This meta-analysis aimed to assess the correlation between various risk factors and CAEs induced by anthracyclines. Methods We systematically searched for studies from PubMed, Cochrane, Embase, and assessed the publication bias. Anthracyclines, hypertension, radiation therapy, diabetes, smoking, age, gender, hyperlipidemia, and obesity were meta-analyzed using a fixed or random effects model. Result Sixteen studies were included in this meta-analysis. The results showed that pooled relative ratio for CAEs was 1.69 (95% CI: 1.39–2.06, p<0.001) for anthracyclines, and that risk factors for CAEs caused by anthracyclines included hypertension (RR = 2.15, 95% CI: 1.53–3.01, p < 0.001), radiation therapy (RR = 1.71, 95% CI: 1.19–2.47, p < 0.001), diabetes (RR = 1.57, 95% CI: 1.20–2.06, p<0.001), smoking (RR = 1.35, 95% CI: 0.96–1.88, p < 0.05), and age (RR = 1.16, 95% CI: 1.07–1.26, p < 0.001). In addition, BMI > 25 kg/m2 (RR = 1.34, 95% CI: 1.08–1.67, p = 0.470), gender (RR = 1.17, 95% CI: 1.06–1.2, p = 0.350), and hyperlipidemia (RR = 1.10, 95% CI: 0.91–1.34, p = 0.327) was not significantly associated with CAEs caused by anthracyclines. Conclusions Our research findings indicate that patients with a history of hypertension, radiation therapy, diabetes, smoking, and elderly individuals are at an elevated risk of cardiovascular disease in the process of administration of anthracycline drugs. Consequently, careful case selection and condition monitoring are important in the treatment process. Graphical Abstract Patients with comorbidities are more prone to suffering from CAEs with anthracycline based chemotherapy, and the risk factors are arranged clockwise in a descending order: hypertension, radiation therapy, diabetes, smoking, age. BMI>25 kg/m2, gender, and hyperlipidemia are not significant associated with CAEs with anthracycline based chemotherapy. |
| format | Article |
| id | doaj-art-80eff8cda8524f9a99d39c87d09c7964 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-80eff8cda8524f9a99d39c87d09c79642025-02-02T12:29:01ZengBMCBMC Cancer1471-24072025-01-0125111210.1186/s12885-024-13305-3A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patientsBo Dai0Jingjing Xu1Baiyan Wang2Xi’an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical UniversityXi’an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical UniversityDepartment of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong UniversityAbstract Background Anthracycline usage has been linked to cardiovascular adverse events (CAEs), which is unpredictable. It is critical to identify the characteristics of vulnerable populations and risk factors in order to reduce the occurrence of CAEs. Objectives This meta-analysis aimed to assess the correlation between various risk factors and CAEs induced by anthracyclines. Methods We systematically searched for studies from PubMed, Cochrane, Embase, and assessed the publication bias. Anthracyclines, hypertension, radiation therapy, diabetes, smoking, age, gender, hyperlipidemia, and obesity were meta-analyzed using a fixed or random effects model. Result Sixteen studies were included in this meta-analysis. The results showed that pooled relative ratio for CAEs was 1.69 (95% CI: 1.39–2.06, p<0.001) for anthracyclines, and that risk factors for CAEs caused by anthracyclines included hypertension (RR = 2.15, 95% CI: 1.53–3.01, p < 0.001), radiation therapy (RR = 1.71, 95% CI: 1.19–2.47, p < 0.001), diabetes (RR = 1.57, 95% CI: 1.20–2.06, p<0.001), smoking (RR = 1.35, 95% CI: 0.96–1.88, p < 0.05), and age (RR = 1.16, 95% CI: 1.07–1.26, p < 0.001). In addition, BMI > 25 kg/m2 (RR = 1.34, 95% CI: 1.08–1.67, p = 0.470), gender (RR = 1.17, 95% CI: 1.06–1.2, p = 0.350), and hyperlipidemia (RR = 1.10, 95% CI: 0.91–1.34, p = 0.327) was not significantly associated with CAEs caused by anthracyclines. Conclusions Our research findings indicate that patients with a history of hypertension, radiation therapy, diabetes, smoking, and elderly individuals are at an elevated risk of cardiovascular disease in the process of administration of anthracycline drugs. Consequently, careful case selection and condition monitoring are important in the treatment process. Graphical Abstract Patients with comorbidities are more prone to suffering from CAEs with anthracycline based chemotherapy, and the risk factors are arranged clockwise in a descending order: hypertension, radiation therapy, diabetes, smoking, age. BMI>25 kg/m2, gender, and hyperlipidemia are not significant associated with CAEs with anthracycline based chemotherapy.https://doi.org/10.1186/s12885-024-13305-3Meta-analysisRisk factorsCardiovascular adverse eventsAnthracycline |
| spellingShingle | Bo Dai Jingjing Xu Baiyan Wang A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients BMC Cancer Meta-analysis Risk factors Cardiovascular adverse events Anthracycline |
| title | A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients |
| title_full | A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients |
| title_fullStr | A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients |
| title_full_unstemmed | A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients |
| title_short | A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients |
| title_sort | meta analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients |
| topic | Meta-analysis Risk factors Cardiovascular adverse events Anthracycline |
| url | https://doi.org/10.1186/s12885-024-13305-3 |
| work_keys_str_mv | AT bodai ametaanalysisofriskfactorsforcardiovascularadverseeventswithanthracyclinebasedchemotherapyinlymphomapatients AT jingjingxu ametaanalysisofriskfactorsforcardiovascularadverseeventswithanthracyclinebasedchemotherapyinlymphomapatients AT baiyanwang ametaanalysisofriskfactorsforcardiovascularadverseeventswithanthracyclinebasedchemotherapyinlymphomapatients AT bodai metaanalysisofriskfactorsforcardiovascularadverseeventswithanthracyclinebasedchemotherapyinlymphomapatients AT jingjingxu metaanalysisofriskfactorsforcardiovascularadverseeventswithanthracyclinebasedchemotherapyinlymphomapatients AT baiyanwang metaanalysisofriskfactorsforcardiovascularadverseeventswithanthracyclinebasedchemotherapyinlymphomapatients |